Proteros Biostructures GmbH (Proteros) announced today that it has entered into a service agreement with Institut Pasteur Korea (IP-K) under which Proteros will provide structure-based drug discovery services to IP-K. Under this collaboration Proteros will apply its know-how, experience of structural analysis and its proprietary X-ray crystallography platform to support IP-K's mission to develop therapeutics for infectious diseases.
Cony D'Cruz, Chief Business Officer of Proteros, stated, "Institut Pasteur Korea is a world class translational research institute, renowned as a centre of excellence in biomedical research and technology development with a clear focus on infectious and neglected disease. We welcome the opportunity for Proteros to contribute to these efforts."
Dr. Michel Liuzzi, Director, Early Discovery Program at IP-K, added "We are very pleased with the expertise and know-how of Proteros in providing timely X-ray crystallography support to our in-house drug discovery projects and we look forward to continue collaborating with Proteros in the future."
Two proteins in the blood could predict dengue severity